{"id":52885,"date":"2023-03-07T04:46:41","date_gmt":"2023-03-07T04:46:41","guid":{"rendered":"https:\/\/insights.greyb.com\/?post_type=ht_kb&p=52885"},"modified":"2025-03-10T05:29:53","modified_gmt":"2025-03-10T05:29:53","slug":"neurocrine-biosciences-patents","status":"publish","type":"ht_kb","link":"https:\/\/insights.greyb.com\/neurocrine-biosciences-patents\/","title":{"rendered":"Neurocrine Biosciences Patents \u2013 Insights & Stats"},"content":{"rendered":"\n

Neurocrine Biosciences has a total of 1588 patents globally, out of which 623 have been granted. Of these 1588 patents, more than 50% patents are active. The United States of America is where Neurocrine Biosciences has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Neurocrine Biosciences.<\/p>\n\n\n\n

Neurocrine Biosciences was founded in the year 1992. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuro inflammatory, and neurodegenerative diseases and disorders. The Company is creating therapeutic interventions for the treatment of anxiety, depression, Alzheimer’s, insomnia, stroke, malignant brain tumours, multiple sclerosis, obesity, and diabetes. As of March 2023, Neurocrine Biosciences has a market cap of $9.72 Billion.<\/p>\n\n\n\n

Do read about some of the most popular patents of Neurocrine Biosciences which have been covered by us in this article and also you can find Neurocrine Biosciences patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Neurocrine Biosciences patent portfolio.<\/p>\n\n\n\n

How many patents does the founder and the CEO of Neurocrine Biosciences have?<\/strong><\/h3>\n\n\n\n

The founders Errol De Souza has 11, Larry Bock has 15, Wylie Vale has 19 patents and CEO Kevin C. Gorman has 0 patents.<\/p>\n\n\n\n

How many patents does <\/strong>Neurocrine Biosciences <\/strong>have?<\/strong><\/h3>\n\n\n\n

Neurocrine Biosciences has a total of 1588 patents globally. These patents belong to 247 unique patent families. Out of 1588 patents, 798 patents are active.<\/p>\n\n\n\n

How Many Patents did <\/strong>Neurocrine Biosciences <\/strong>File Every Year?<\/strong><\/h3>\n\n\n\n
\"Neurocrine<\/a><\/figure>\n\n\n\n

Are you wondering why there is a drop in patent filing for the last two years? <\/strong>It is because a patent application can take up to 18 months to get published. Certainly, it doesn\u2019t suggest a decrease in the patent filing.<\/p>\n\n\n\n

Year of Patents Filing or Grant<\/strong><\/strong><\/td>Neurocrine Biosciences Applications Filed<\/strong><\/strong><\/td>Neurocrine Biosciences Patents Granted<\/strong><\/strong><\/td><\/tr>
2023<\/td>–<\/td>3<\/td><\/tr>
2022<\/td>48<\/td>62<\/td><\/tr>
2021<\/td>69<\/td>72<\/td><\/tr>
2020<\/td>121<\/td>47<\/td><\/tr>
2019<\/td>81<\/td>9<\/td><\/tr>
2018<\/td>71<\/td>13<\/td><\/tr>
2017<\/td>86<\/td>19<\/td><\/tr>
2016<\/td>124<\/td>11<\/td><\/tr>
2015<\/td>67<\/td>13<\/td><\/tr>
2014<\/td>33<\/td>14<\/td><\/tr>
2013<\/td>33<\/td>19<\/td><\/tr>
2012<\/td>24<\/td>31<\/td><\/tr>
2011<\/td>10<\/td>17<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Which Neurocrine Biosciences<\/strong> Drug Patents are Expiring in the Next 10 Years?<\/strong><\/h3>\n\n\n\n

The patent no. US10065952B2<\/a> which is expiring in Oct, 2036, describes treating hyperkinetic movement disorders, including symptoms of tardive dyskinesia, involves giving a pharmaceutically acceptable salt of (S)-2-amino-3-methyl-butyric acid in specific forms. This can be in amorphous or crystalline states. The process of making these forms and the resulting pharmaceutical compositions are also part of the treatment.<\/p>\n\n\n\n

Given below is the list of few drugs patented by Neurocrine Biosciences <\/strong>accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next\/upcoming 10 years for treatment of various diseases and disorders.<\/p>\n\n\n\n

Drug Name<\/strong><\/td>Patent Number<\/strong><\/td>Patent Title<\/strong><\/td>Patent Expiration<\/strong><\/td><\/tr>
Ingrezza<\/a><\/td>US10065952B2<\/a><\/td>Valbenazine Salts And Polymorphs…<\/td>Oct, 2036<\/td><\/tr>
Ongentys<\/a><\/td>US8168793B2<\/a><\/td>Nitrocatechol Derivatives As COMT…<\/td>Apr, 2029<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n
\n

Interested in knowing about Neurocrine Biosciences Drug Patents Expiring in the next 10 years?<\/h3>\n<\/div>\n
\n
Get the Data<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n

How many Neurocrine Biosciences<\/strong> <\/strong>patents are Alive\/Dead?<\/strong><\/h3>\n\n\n\n
\"Neurocrine<\/a><\/figure>\n\n\n\n

<\/strong>How Many Patents did <\/strong>Neurocrine Biosciences <\/strong>File in Different Countries?<\/strong><\/strong><\/h3>\n\n\n\n
\"Neurocrine<\/a><\/figure>\n\n\n\n

Countries in which <\/strong>Neurocrine Biosciences <\/strong>Filed Patents<\/strong><\/h3>\n\n\n\n
Country<\/strong><\/td>Patent<\/strong><\/td><\/tr>
United States Of America<\/td>200<\/td><\/tr>
Japan<\/td>108<\/td><\/tr>
Europe<\/td>96<\/td><\/tr>
Australia<\/td>81<\/td><\/tr>
China<\/td>64<\/td><\/tr>
Mexico<\/td>57<\/td><\/tr>
Canada<\/td>57<\/td><\/tr>
Hong Kong (S.A.R.)<\/td>53<\/td><\/tr>
Korea (South)<\/td>51<\/td><\/tr>
United Kingdom<\/td>42<\/td><\/tr>
Germany<\/td>42<\/td><\/tr>
Israel<\/td>39<\/td><\/tr>
Brazil<\/td>37<\/td><\/tr>
Spain<\/td>35<\/td><\/tr>
India<\/td>35<\/td><\/tr>
Taiwan<\/td>31<\/td><\/tr>
Austria<\/td>29<\/td><\/tr>
Singapore<\/td>28<\/td><\/tr>
South Africa<\/td>26<\/td><\/tr>
Norway<\/td>24<\/td><\/tr>
New Zealand<\/td>23<\/td><\/tr>
Portugal<\/td>23<\/td><\/tr>
Denmark<\/td>23<\/td><\/tr>
Indonesia<\/td>19<\/td><\/tr>
Viet Nam<\/td>18<\/td><\/tr>
Argentina<\/td>17<\/td><\/tr>
Malaysia<\/td>17<\/td><\/tr>
Poland<\/td>16<\/td><\/tr>
Russia<\/td>16<\/td><\/tr>
Eurasia<\/td>14<\/td><\/tr>
Philippines<\/td>13<\/td><\/tr>
Chile<\/td>12<\/td><\/tr>
Malta<\/td>11<\/td><\/tr>
Slovenia<\/td>9<\/td><\/tr>
Pakistan<\/td>9<\/td><\/tr>
Croatia<\/td>9<\/td><\/tr>
Hungary<\/td>9<\/td><\/tr>
Peru<\/td>8<\/td><\/tr>
Morocco<\/td>8<\/td><\/tr>
Lithuania<\/td>7<\/td><\/tr>
Serbia<\/td>7<\/td><\/tr>
Uruguay<\/td>4<\/td><\/tr>
Italy<\/td>4<\/td><\/tr>
Jordan<\/td>4<\/td><\/tr>
Turkey<\/td>3<\/td><\/tr>
Cyprus<\/td>3<\/td><\/tr>
Albania<\/td>3<\/td><\/tr>
Africa<\/td>4<\/td><\/tr>
Tunisia<\/td>3<\/td><\/tr>
Iceland<\/td>3<\/td><\/tr>
Colombia<\/td>3<\/td><\/tr>
Panama<\/td>2<\/td><\/tr>
Costa Rica<\/td>2<\/td><\/tr>
Slovakia<\/td>2<\/td><\/tr>
Bangladesh<\/td>2<\/td><\/tr>
United Arab Emirates<\/td>2<\/td><\/tr>
Saudi Arabia<\/td>2<\/td><\/tr>
Montenegro<\/td>1<\/td><\/tr>
Gulf Cooperation Council<\/td>1<\/td><\/tr>
Czech Republic<\/td>1<\/td><\/tr>
Former Yugoslav Republic of Macedonia<\/td>1<\/td><\/tr>
Estonia<\/td>1<\/td><\/tr>
Ecuador<\/td>1<\/td><\/tr>
Mongolia<\/td>1<\/td><\/tr>
Ukraine<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Where are Research Centres of Neurocrine Biosciences Patents Located?<\/strong><\/h3>\n\n\n\n
\"R&D<\/a><\/figure>\n\n\n\n

10 Best <\/strong>Neurocrine Biosciences <\/strong>Patents<\/strong><\/h3>\n\n\n\n

WO2005040109A1<\/a> is the most popular patent in the Neurocrine Biosciences portfolio. It has received 262 citations so far from companies like Merck & Co, Xenon Pharmaceuticals and Sanofi.<\/strong><\/p>\n\n\n\n

Below is the list of 10 most cited patents of Neurocrine Biosciences:<\/strong><\/h3>\n\n\n\n
Publication Number<\/strong><\/td>Citation Count<\/strong><\/td><\/tr>
WO2005040109A1<\/a><\/td>262<\/td><\/tr>
WO2003031410A1<\/a><\/td>177<\/td><\/tr>
WO2008058261A1<\/a><\/td>158<\/td><\/tr>
WO2003094918A1<\/a><\/td>148<\/td><\/tr>
WO2003068738A1<\/a><\/td>118<\/td><\/tr>
US8039627B2<\/a><\/td>108<\/td><\/tr>
US6399621B1<\/a><\/td>107<\/td><\/tr>
WO2008070661A1<\/a><\/td>100<\/td><\/tr>
WO2005007165A1<\/a><\/td>95<\/td><\/tr>
WO2009062087A1<\/a><\/td>92<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How many inventions of other companies were rejected due to Neurocrine Biosciences patents?<\/strong><\/h3>\n\n\n\n

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Neurocrine Biosciences invention. They couldn\u2019t because Neurocrine Biosciences had protected those before them.<\/strong><\/p>\n\n\n\n

Examiners at the USPTO referred 22 Neurocrine Biosciences patents in 51 rejections (35 USC \u00a7 102 or 35 USC \u00a7 103 types).<\/p>\n\n\n\n

The top citing companies in the Neurocrine Biosciences patent portfolio are Spruce Biosciences, Auspex Pharmaceuticals and Abbvie.<\/strong><\/p>\n\n\n\n

List of the Companies whose Patents were rejected citing Neurocrine Biosciences \u2013<\/p>\n\n\n\n

Company<\/strong><\/strong><\/td>Number of Patent Applications that faced Rejection Citing Neurocrine Biosciences Patents<\/strong><\/strong><\/td>Number of Rejections (102 & 103)<\/strong><\/strong><\/td><\/tr>
Spruce Biosciences<\/td>2<\/td>3<\/td><\/tr>
Auspex Pharmaceuticals<\/td>2<\/td>2<\/td><\/tr>
Abbvie<\/td>2<\/td>8<\/td><\/tr>
Sequential Medicine<\/td>2<\/td>2<\/td><\/tr>
Nihon Kohden<\/td>1<\/td>1<\/td><\/tr>
Jagotec<\/td>1<\/td>1<\/td><\/tr>
United States Secretary of Army<\/td>1<\/td>1<\/td><\/tr>
Assia Chemical Industries<\/td>1<\/td>1<\/td><\/tr>
Millennium Pharmaceuticals<\/td>1<\/td>1<\/td><\/tr>
Addex Pharmaceuticals<\/td>1<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Count of 102 and 103 Type Rejections based on Neurocrine Biosciences Patents<\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n

Top<\/strong> Neurocrine Biosciences Patents used in Rejecting Most Patent Applications<\/strong><\/h3>\n\n\n\n
Patent Number<\/strong><\/strong><\/td>Count of Rejected Applications<\/strong><\/strong><\/td><\/tr>
US8039627B2<\/td>4<\/td><\/tr>
US6485746B1<\/td>4<\/td><\/tr>
US20170020877A1<\/td>2<\/td><\/tr>
US7771632B2<\/td>2<\/td><\/tr>
US8765948B2<\/td>2<\/td><\/tr>
US9012436B2<\/td>2<\/td><\/tr>
US7034118B2<\/td>1<\/td><\/tr>
US6399621B1<\/td>1<\/td><\/tr>
US20050192286A1<\/td>1<\/td><\/tr>
US20040157851A1<\/td>1<\/td><\/tr>
US6750350B2<\/td>1<\/td><\/tr>
US20050176738A1<\/td>1<\/td><\/tr>
US7419983B2<\/td>1<\/td><\/tr>
US9649280B2<\/td>1<\/td><\/tr>
US20030091632A1<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Percentage <\/strong>of Neurocrine Biosciences US Patent Applications were Granted?<\/strong><\/h3>\n\n\n\n

Neurocrine Biosciences (Excluding its subsidiaries) has filed 267 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 128 have been granted leading to a grant rate of 61.24%<\/strong>.<\/p>\n\n\n\n

Below are the key stats of Neurocrine Biosciences patent prosecution at the USPTO.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Which Law Firms Filed Most US Patents for <\/strong>Neurocrine Biosciences<\/strong>?<\/strong><\/h3>\n\n\n\n
Law Firm<\/strong><\/strong><\/td>Total Applications<\/strong><\/strong><\/td>Success Rate<\/strong><\/strong><\/td><\/tr>
Seed IP<\/td>125<\/td>79.17%<\/td><\/tr>
Fish & Richardson<\/td>79<\/td>55.71%<\/td><\/tr>
Global Patent Group<\/td>17<\/td>80.00%<\/td><\/tr>
Glaxosmithkline<\/td>9<\/td>44.44%<\/td><\/tr>
C O Vp Ip Legal<\/td>6<\/td>83.33%<\/td><\/tr>
Cooley Llp<\/td>6<\/td>0.00%<\/td><\/tr>
Neurocrine Biosciences<\/td>5<\/td>100.00%<\/td><\/tr>
Karl R Hermanns<\/td>3<\/td>100.00%<\/td><\/tr>
Scully Scott Murphy & Presser<\/td>3<\/td>100.00%<\/td><\/tr>
Pfizer<\/td>2<\/td>100.00%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What are <\/strong><\/strong><\/strong><\/strong><\/strong><\/strong>Neurocrine Biosciences<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong> key innovation segments?<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h3>\n\n\n\n\n